Migraine Treatment & Prevention Guide

Migraine is the second most disabling neurological condition worldwide and the leading cause of disability in people under 50.^[7] Yet in my experience, most patients I see for the first time have either been undertreated for years, relying on over-the-counter medications that do not adequately control their attacks, or overtreated — taking acute medications so frequently that the medications themselves are now driving daily headaches.

The good news is that migraine management has changed substantially over the past five years. We now have migraine-specific preventive therapies — CGRP monoclonal antibodies — that are both more effective and better tolerated than older oral agents for most patients. Acute treatment options have expanded with the gepants. And the American Headache Society (AHS), in its 2024 updated consensus statement, shifted the standard of care by placing these newer therapies earlier in the treatment algorithm.^[2]

This guide covers what you need to know: how migraine is diagnosed, what the current treatment options look like, when preventive therapy makes sense, and how to avoid the common pitfalls that trap patients in a cycle of worsening headache.

What Migraine Actually Is

Migraine is not simply a "bad headache." It is a neurological disorder involving abnormal brain activity that triggers a cascade of pain and sensory symptoms. The pain — typically unilateral, throbbing, moderate to severe — is accompanied by nausea, sensitivity to light (photophobia), and sensitivity to sound (phonophobia) in most cases. Physical activity makes it worse. Attacks last 4 to 72 hours untreated.

The underlying biology centers on calcitonin gene-related peptide (CGRP), a protein released from trigeminal nerve endings during a migraine attack. CGRP causes vasodilation and promotes pain transmission in the trigeminal pain system. This is why the most effective migraine-specific treatments — triptans and CGRP-targeted therapies — work by interrupting this pathway.^[2]

Migraine With Aura vs. Without Aura

Roughly 25–30% of people with migraine experience aura — transient neurological symptoms that precede or accompany the headache phase. The most common aura is visual: zigzag lines, bright spots, or a spreading blind spot (scotoma) that builds over 5–20 minutes and resolves within an hour. Sensory aura (tingling or numbness in the face or hand) and language disruption are less common.

Migraine with aura carries specific clinical implications. Combined estrogen-progestin oral contraceptives are relatively contraindicated because they increase stroke risk in women who have aura, a recommendation that has been reinforced in cardiology and neurology guidelines.^[7] Certain aura types — hemiplegic migraine, migraine with brainstem aura — warrant specialist evaluation to rule out other conditions.

Episodic vs. Chronic Migraine

Episodic migraine is defined as fewer than 15 headache days per month. Chronic migraine means 15 or more headache days per month for over three months, with at least eight meeting migraine criteria. Chronification — the progression from episodic to chronic — affects about 3% of episodic migraine patients per year and is often driven by inadequate acute treatment and medication overuse. This progression is not inevitable; the right preventive strategy early in the course can interrupt it.

Acute Treatment: Stopping an Attack

The goal of acute treatment is straightforward — stop the attack as quickly and completely as possible, and keep it from coming back within 24 hours. The critical principle is timing: treat at the first sign of pain, while it is still mild. Waiting until pain is severe significantly reduces the effectiveness of any treatment.^[7]

Triptans: The First-Line Standard

Triptans are serotonin (5-HT_1B/1D) receptor agonists specifically designed to abort migraine attacks. They constrict dilated meningeal blood vessels, inhibit CGRP release, and block pain signal transmission in the trigeminal system. Seven oral triptans are available in the U.S.; all are effective, but they differ in speed of onset, duration of action, and tolerability.

Sumatriptan is the most extensively studied triptan and remains the reference standard.^[3] The subcutaneous 6 mg injection is the most effective formulation — achieving pain freedom at two hours in about 59% of patients — but the oral 50–100 mg tablets are the practical choice for most patients. What I tell patients is to take sumatriptan at the onset of head pain, not during aura, and to take a full effective dose rather than starting low.

NSAIDs and Acetaminophen

For mild-to-moderate attacks, NSAIDs are effective and appropriate first-line options. Naproxen sodium 500–550 mg, ibuprofen 400–800 mg, and aspirin 900–1000 mg (with antiemetic if needed) all have good evidence for migraine acute treatment.^[3] The combination of sumatriptan plus naproxen sodium is superior to either agent alone — a fixed-dose combination (Treximet) is available, though using sumatriptan 50 mg plus naproxen 500 mg separately is clinically equivalent and more cost-effective.

Acetaminophen 1000 mg is a reasonable option for patients who cannot take NSAIDs or triptans, though its efficacy for migraine is modest compared to triptans or NSAIDs.

Gepants: A New Class of Acute and Preventive Treatment

Gepants are small-molecule CGRP receptor antagonists that work without the vasoconstriction associated with triptans, making them suitable for patients with cardiovascular disease or contraindications to triptans.

• Ubrogepant (Ubrelvy) — 50–100 mg oral tablet for acute migraine. Effective at reducing pain and most bothersome symptoms within two hours. Can be taken with a second dose two hours after the first if needed.
• Rimegepant (Nurtec ODT) — 75 mg orally dissolving tablet that uniquely serves dual purposes: it is both an acute treatment and an approved preventive agent when taken every other day. This makes it a particularly versatile option for patients with moderate headache frequency.

Gepants do not appear to cause medication overuse headache at the same rate as triptans or analgesics — emerging evidence suggests they may actually reduce medication overuse when used in place of traditional acute agents.^[2] This is a meaningful clinical advantage for patients who are already prone to high-frequency headache.

Anti-Nausea Medications

Nausea is a major barrier to effective acute treatment — if you cannot keep a tablet down, no oral medication will work. Prochlorperazine, metoclopramide, and promethazine are effective anti-nausea agents that also have independent analgesic effects in migraine. The 2025 AHS guideline update for emergency department management elevated prochlorperazine IV to a Level A ("must offer") recommendation, reflecting consistently strong evidence across multiple high-quality trials.^[1]

Preventive Therapy: Who Needs It and What Works

Preventive therapy is one of the most underused treatments in medicine. Studies consistently show that only about 13% of patients who qualify for prevention are actually receiving it.^[4] That gap represents a large number of people experiencing preventable disability.

When to Consider Prevention

Most guidelines, including the American Academy of Family Physicians, recommend discussing preventive therapy when any of the following apply:^[4]

• Four or more headache days per month (some guidelines cite eight or more migraine days)
• Attacks that significantly impair function despite good acute treatment
• Frequent use of acute medications — more than two to three treatment days per week — creating risk for medication overuse headache
• Contraindication or intolerance to acute therapies
• Special migraine subtypes (hemiplegic, brainstem aura, frequent prolonged aura)
• Patient preference for reducing attack frequency

Traditional Oral Preventive Agents

CGRP Monoclonal Antibodies: The New Standard

The approval of the first CGRP monoclonal antibody in 2018 changed migraine prevention in a meaningful way. These agents are the first preventive treatments designed specifically for migraine — not repurposed from cardiology or neurology for other indications.

Three subcutaneous monthly (or quarterly) self-injections are FDA-approved for episodic and chronic migraine prevention:

• Erenumab (Aimovig) — 70 mg or 140 mg monthly self-injection. Uniquely targets the CGRP receptor (rather than the CGRP protein itself). The APPRAISE trial (2024) showed that 56% of patients on erenumab achieved a ≥50% reduction in monthly migraine days, versus only 16% on traditional oral preventives — a striking difference demonstrating the advantage of earlier CGRP access.^[2]
• Fremanezumab (Ajovy) — 225 mg monthly or 675 mg every three months (three consecutive injections). Targets the CGRP protein. Meta-analysis data rank fremanezumab highly for both efficacy and tolerability.^[5]
• Galcanezumab (Emgality) — 120 mg monthly (240 mg loading dose). Targets the CGRP protein. Phase III EVOLVE trials showed average monthly migraine day reductions of 4.7 days versus 2.8 days on placebo at the 120 mg dose.^[2]

A fourth option, eptinezumab (Vyepti), is administered as a quarterly IV infusion and is particularly useful for patients who have had difficulty with self-injection therapies.

The side effect profile of CGRP antibodies is generally favorable — the most common complaints are injection site reactions and constipation (more frequent with erenumab). No new long-term safety signals have emerged in studies extending to three years.^[2] Insurance coverage can be a barrier; prior authorization is typically required, and demonstrating adequate trial of oral preventives may still be necessary depending on your plan.

Medication Overuse Headache: The Hidden Driver

Medication overuse headache (MOH) is one of the most common — and most commonly missed — diagnoses in headache medicine. Here is the paradox: the medications you are taking to relieve your headache are making you have more headaches.

The ICHD-3 diagnostic criteria for MOH require:^[5b]

• Headache occurring on 15 or more days per month in someone with a pre-existing headache disorder
• Regular overuse of acute headache medications for over three months
• The pattern is not better explained by another diagnosis

The specific usage threshold varies by medication class. Triptans, ergotamines, opioids, and combination analgesics cross the overuse threshold at 10 or more days per month. Simple analgesics like acetaminophen, aspirin, and NSAIDs reach the threshold at 15 or more days per month. The biology behind MOH involves central sensitization — the brain's pain processing system becomes chronically activated, lowering the threshold for new attacks.

What I see most often in practice: a patient with episodic migraine starts using their acute medication more frequently as headaches intensify. The medication works, so they use it again. Over months, they shift from 4 headache days per month to 15 or more, with a dull background headache present most days. The acute medication still provides brief relief, reinforcing the behavior. By the time they see a physician, they often believe their migraine has simply "gotten worse" — and they are partly right, but the medication is a significant driver.

Treatment requires supervised withdrawal of the overused medication. This is uncomfortable — rebound headaches intensify for one to two weeks before improving — but the outcome is typically good. Adding a preventive medication during or after withdrawal significantly improves success rates. Gepants appear less likely to cause MOH than triptans or analgesics, which is an emerging advantage for high-frequency migraine patients.^[2]

Menstrual Migraine

Menstrual migraine refers to attacks that cluster predictably around menstruation — typically occurring two days before through three days after the onset of bleeding. These attacks are driven by the sharp drop in estrogen levels that precedes the period. Compared to non-menstrual migraine attacks, they tend to be longer, more severe, more likely to be associated with nausea, and less responsive to standard acute treatments.

Two broad management strategies apply. The first is optimized acute treatment — using the most effective acute medication at the earliest sign of the attack. Triptans with longer half-lives (frovatriptan, naratriptan) are often preferred because they are less likely to require repeat dosing.

The second strategy is mini-prophylaxis: short-term preventive treatment starting two to three days before the expected onset of menstruation. Frovatriptan 2.5 mg twice daily for six days perimenstrually has Level A evidence for menstrual migraine prevention — it is the only triptan with this specific evidence-based indication.^[8] NSAIDs taken perimenstrually are also used, particularly for women who cannot take triptans daily.

For women on hormonal contraception, the approach depends on whether they have aura. Estrogen-containing contraceptives are relatively contraindicated in migraine with aura. Progestin-only options are generally safe and, in some women, improve menstrual migraine by eliminating the estrogen fluctuation that triggers attacks.

Triggers, the Headache Diary, and What Actually Causes Your Attacks

Every patient I see with migraine has a trigger they believe they need to eliminate. Chocolate, red wine, aged cheese. The reality is more complicated — and more useful.

Triggers do not cause migraine attacks directly. They lower the threshold in a brain that is already primed for an attack. Most attacks require multiple factors converging — hormonal changes plus poor sleep plus skipping a meal, for example. This means avoiding a single trigger often does not prevent attacks, and being overly restrictive about triggers can worsen quality of life without meaningful benefit.

The well-supported, modifiable triggers include:

• Sleep disruption — both insufficient sleep and sleeping too much are triggers. Regular sleep timing matters more than duration for most migraine patients.
• Psychological stress — not stress itself, but the stress response and particularly the "let-down" after a stressful period (weekend migraine is a classic example).
• Hormonal changes — the most reliable biological trigger, especially the estrogen drop before menstruation.
• Skipped meals and dehydration — blood glucose fluctuations and dehydration reliably lower migraine threshold in susceptible individuals.
• Caffeine — both excess intake and withdrawal trigger attacks. Consistency matters; the goal is a stable, moderate intake, not elimination.
• Sensory stimuli — bright or flickering light, strong odors, and loud sustained noise can trigger attacks in some patients.

A headache diary — recording date, duration, severity, associated symptoms, possible triggers, and medications used — is the single most useful tool for identifying your personal pattern. It also provides the objective data your physician needs to assess preventive therapy response. Several validated diary apps are available (Migraine Buddy, N1 Headache) and work better than paper for most patients.

Red Flags: When a Headache Is Not Migraine

Every physician who treats headache has at least one patient in mind who presented with "their usual migraine" and turned out to have a subarachnoid hemorrhage. The lesson is not to panic every headache patient, but to apply systematic screening for warning signs.

The SNOOP criteria summarize the key red flags for secondary (dangerous) headache:^[6]

• S — Systemic symptoms: Fever, unintentional weight loss, or systemic illness suggesting infection, malignancy, or an inflammatory condition (e.g., temporal arteritis in patients over 50).
• N — Neurologic symptoms or signs: New focal deficit — weakness, numbness, speech difficulty, vision changes other than typical migraine aura — or altered consciousness.
• O — Onset: sudden or thunderclap: A headache that reaches maximum intensity in seconds to minutes is a subarachnoid hemorrhage until proven otherwise. This is the most critical red flag.
• O — Older age at onset: New headache after age 50 (some criteria use 40) warrants more thorough evaluation, including consideration of giant cell arteritis, intracranial mass, or vascular disease.
• P — Pattern change: A meaningfully different headache from your typical pattern — new location, new quality, increasing frequency without explanation, or failure to respond to previously effective treatment.

Additional warning features include headache triggered by exertion, coughing, or Valsalva (suggesting posterior fossa pathology); positional headache (worsening when standing, suggesting intracranial hypotension); and headache with papilledema (suggesting elevated intracranial pressure). Headache during pregnancy or postpartum requires urgent evaluation given the risk of cerebral venous sinus thrombosis and hypertensive disorders.^[6]

Status Migrainosus

Status migrainosus is defined as a migraine attack lasting more than 72 hours — either continuously or with brief intervals of less than four hours free of pain. It is debilitating and typically does not respond to standard outpatient acute medications by the time patients seek help, often because those medications have already been used repeatedly without adequate relief.

Management escalates beyond typical outpatient options. Treatment usually involves rehydration with IV fluids, IV antiemetics (prochlorperazine is preferred based on current AHS evidence), IV ketorolac, and sometimes IV valproate or IV magnesium sulfate.^[1] A single dose of IV or IM dexamethasone is used to prevent recurrence after discharge, though the 2025 AHS guideline notes that evidence for its role in acute pain relief is more limited than its recurrence-prevention role.

Do not try to manage status migrainosus at home. Patients who present to the emergency department tend to do better with IV medications than with any oral regimen at that stage of an attack. If your migraine has lasted more than two days and is not improving, seek care.

Managing Migraine Through Telehealth

Most migraine care is well suited to telehealth. The diagnosis of migraine is clinical — it is made from the history, not from imaging or lab tests — and the ongoing management of a known diagnosis requires physician review, not physical examination, in most cases.

What we do effectively via telehealth at TeleDirectMD:

• Initial evaluation of headache history to diagnose episodic or chronic migraine
• Prescribing and refilling acute medications (triptans, gepants, anti-nausea agents)
• Initiating and monitoring preventive therapy, including CGRP monoclonal antibodies when appropriate
• Reviewing headache diary data to assess treatment response and adjust plans
• Identifying medication overuse headache and developing a supervised withdrawal plan
• Discussing hormonal considerations for women with migraine, including contraception guidance

In-person or specialist evaluation remains important for new or changing headache patterns that warrant imaging, for suspected hemiplegic or basilar migraine, for patients who have failed multiple preventive therapies, and when neurological examination is required. We will refer appropriately when that bar is met. For the large majority of migraine patients — those with a clear diagnosis, stable pattern, and reasonable treatment response — telehealth visits are more convenient and equally effective.^[9]

To reach us: call 678-956-1855 or email contact@teledirectmd.com.